Hyperbaric oxygen

ApprovedSmall molecule

IIntermountain Health Care, Inc.

Hyperbaric oxygen is one of 349 small molecule programs targeting Pyoderma Gangrenosum. It is currently in Approved.

Indications

Total Trials

Active Trials

348

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pyoderma GangrenosumActive, not recruiting

StrokeActive, not recruiting

AmputationActive, not recruiting

Brain InjuryActive, not recruiting

NecrosisActive, not recruiting

EndocarditisActive, not recruiting

OsteoradionecrosisActive, not recruiting

COVID-19Active, not recruiting

Soft Tissue SarcomaActive, not recruiting

CystitisActive, not recruiting

Pyoderma GangrenosumPhase 3

Active, not recruiting

StrokePhase 2

Active, not recruiting

AmputationPhase 1/Phase 2

Active, not recruiting

Brain InjuryPhase 3

Active, not recruiting

NecrosisPreclinical

Active, not recruiting

EndocarditisPhase 2

Active, not recruiting

OsteoradionecrosisPhase 2/Phase 3

Active, not recruiting

COVID-19Phase 3

Active, not recruiting

Soft Tissue SarcomaApproved

Active, not recruiting

CystitisPhase 2/Phase 3

Active, not recruiting

Showing 10 of 13 indications

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Hyperbaric oxygen

IIntermountain Health Care, Inc.

Approved

2 2

Bnt162b2

BioNTech

Preclinical

29 3

Aimovig

Amgen

Preclinical

1 4

Stivarga

Bayer

Preclinical

1 5

Activella

Eli Lilly

Preclinical

—6

Calciferol

Alnylam Pharmaceuticals

Preclinical

—7

Piperacillin/tazobactam

Pfizer

Preclinical

1 8

Glucocorticoid

AbbVie

Preclinical

1 9

Nadroparin

GSK

Preclinical

1 10

Achromycin V

WWyeth-Lederle Vaccines

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Soft Tissue Sarcoma

NCT03144206

Q1 2027

Phase 1Recruiting

Hyperbaric Oxygen Therapy

NCT03964506

Q2 2027

Phase 2Recruiting

Stem Cell Transplant

NCT03739502

Q1 2028

Phase 3Recruiting

Injury

NCT06526728

Clinical

Trials by Indication[1]

Brain Injury3 trials

Hyperbaric Oxygen Therapy (HBO2) for Persistent Post-concussive Symptoms After Mild Traumatic Brain Injury (mTBI)

Completed·UU.S. Army Medical Research and Development Command·Phase 2·NCT01306968·79 enrolled

Hyperbaric Oxygen Treatment to Treat Mild Traumatic Brain Injury (mTBI)/Persistent Post-Concussion Syndrome (PPCS)

Unknown status·LLouisiana State University Health Sciences Center in New Orleans·Phase 3·NCT02089594·59 enrolled

Hyperbaric Oxygen Brain Injury Treatment Trial

Recruiting·GGaylan Rockswold·Phase 2·NCT02407028·200 enrolled

Injury3 trials

Hyperbaric Oxygen Therapy Attenuates Central Sensitization Induced by a Thermal Injury in Human Volunteers (HBO)

Completed·PPer Rotbøll Nielsen·N/A·NCT02025686·16 enrolled

The Effect of Hyperbaric Oxygen Therapy on Inflammatory Parameters Induced by a Heat Injury Model

Completed·RRigshospitalet, Denmark·Phase 2·NCT02397343·26 enrolled

Hyperbaric Oxygen Therapy in HAMstring Injury (HOTHAM) Trial

Recruiting·JJL Tol·Phase 3·NCT06526728·50 enrolled

Stroke3 trials

Effects of Repetitive Hyperbaric Oxygen Therapy in Patients With Acute Ischaemic Stroke

Unknown status·KKasr El Aini Hospital·N/A·NCT03431402·60 enrolled

Hyperbaric Oxygen in Patients Who Had a Stroke

Completed·HHyperbaric Center Basel·Phase 4·NCT04297358·10 enrolled

Hyperbaric Oxygen Therapy After Stroke - PILOT

Withdrawn·NNorwegian Underwater Intervention (NUI)·Phase 2·NCT04149379